171 related articles for article (PubMed ID: 21703320)
1. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia.
Gray RT; Ghaus MH; Hoare A; Wilson DP
Vaccine; 2011 Aug; 29(36):6125-9. PubMed ID: 21703320
[TBL] [Abstract][Full Text] [Related]
2. The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: a modeling study.
Nagelkerke NJ; Hontelez JA; de Vlas SJ
Vaccine; 2011 Aug; 29(36):6079-85. PubMed ID: 21718745
[TBL] [Abstract][Full Text] [Related]
3. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
Andersson KM; Stover J
Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
[TBL] [Abstract][Full Text] [Related]
4. Expected epidemiological impacts of introducing an HIV vaccine in Thailand: a model-based analysis.
Schneider K; Kerr CC; Hoare A; Wilson DP
Vaccine; 2011 Aug; 29(36):6086-91. PubMed ID: 21723902
[TBL] [Abstract][Full Text] [Related]
5. The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model.
Hontelez JA; Nagelkerke N; Bärnighausen T; Bakker R; Tanser F; Newell ML; Lurie MN; Baltussen R; de Vlas SJ
Vaccine; 2011 Aug; 29(36):6100-6. PubMed ID: 21703321
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
Long EF; Owens DK
Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
[TBL] [Abstract][Full Text] [Related]
7. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results.
Andersson KM; Paltiel AD; Owens DK
Vaccine; 2011 Aug; 29(36):6107-12. PubMed ID: 21736912
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adult circumcision in a resource-rich setting for HIV prevention among men who have sex with men.
Anderson J; Wilson D; Templeton DJ; Grulich A; Carter R; Kaldor J
J Infect Dis; 2009 Dec; 200(12):1803-12. PubMed ID: 19909084
[TBL] [Abstract][Full Text] [Related]
9. Treatment for prevention of HIV transmission in a localised epidemic: the case for South Australia.
Heymer KJ; Wilson DP
Sex Health; 2011 Sep; 8(3):280-94. PubMed ID: 21851767
[TBL] [Abstract][Full Text] [Related]
10. Circumcision status and HIV infection among MSM: reanalysis of a Phase III HIV vaccine clinical trial.
Gust DA; Wiegand RE; Kretsinger K; Sansom S; Kilmarx PH; Bartholow BN; Chen RT
AIDS; 2010 May; 24(8):1135-43. PubMed ID: 20168206
[TBL] [Abstract][Full Text] [Related]
11. The impact of the transmission dynamics of the HIV/AIDS epidemic on sexual behaviour: a new hypothesis to explain recent increases in risk taking-behaviour among men who have sex with men.
Boily MC; Godin G; Hogben M; Sherr L; Bastos FI
Med Hypotheses; 2005; 65(2):215-26. PubMed ID: 15922091
[TBL] [Abstract][Full Text] [Related]
12. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand.
Newman PA; Roungprakhon S; Tepjan S; Yim S
Vaccine; 2010 Jan; 28(4):958-64. PubMed ID: 19925897
[TBL] [Abstract][Full Text] [Related]
13. The potential global market size and public health value of an HIV-1 vaccine in a complex global market.
Marzetta CA; Lee SS; Wrobel SJ; Singh KJ; Russell N; Esparza J
Vaccine; 2010 Jul; 28(30):4786-97. PubMed ID: 20471439
[TBL] [Abstract][Full Text] [Related]
14. Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003.
Martin M; Vanichseni S; Suntharasamai P; Mock PA; van Griensven F; Pitisuttithum P; Tappero JW; Chiamwongpaet S; Sangkum U; Kitayaporn D; Gurwith M; Choopanya K;
Int J Drug Policy; 2010 Jul; 21(4):296-301. PubMed ID: 20079620
[TBL] [Abstract][Full Text] [Related]
15. Modeling the population level effects of an HIV-1 vaccine in an era of highly active antiretroviral therapy.
Rida W; Sandberg S
Bull Math Biol; 2009 Apr; 71(3):648-80. PubMed ID: 19214640
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
17. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.
Selinger C; Bershteyn A; Dimitrov DT; Adamson BJS; Revill P; Hallett TB; Phillips AN; Bekker LG; Rees H; Gray G
Vaccine; 2019 Apr; 37(16):2258-2267. PubMed ID: 30890385
[TBL] [Abstract][Full Text] [Related]
18. Potential public health impact of imperfect HIV type 1 vaccines.
Anderson R; Hanson M
J Infect Dis; 2005 Feb; 191 Suppl 1():S85-96. PubMed ID: 15627235
[TBL] [Abstract][Full Text] [Related]
19. How low can you go: the impact of a modestly effective HIV vaccine compared with male circumcision.
Kaldor JM; Wilson DP
AIDS; 2010 Oct; 24(16):2573-8. PubMed ID: 20829677
[TBL] [Abstract][Full Text] [Related]
20. Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine.
Lampinen TM; Chan K; Remis RS; Merid MF; Rusch M; Vincelette J; Logue K; Popovic V; Alary M; Schechter MT; Hogg RS
CMAJ; 2005 Feb; 172(4):479-83. PubMed ID: 15710939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
